['breast cancer']
['neoadjuvant chemotherapy', 'postoperative chemotherapy']

        Inclusion Criteria:

          1. Invasive breast cancer confirmed by pathology evaluation of core biopsy

          2. Tumors must be ER/PgR status negative (immunohistochemistry（IHC） < 10%) and lack of
             HER2/neu overexpression or amplification as measured by local hospital pathology
             laboratory (IHC +/- fluorescence in situ hybridization (FISH) and IHC < 3+, and FISH <
             2.2) as described in the NCCN Guidelines

          3. Female between18 to 70 years of age, Eastern Cooperative Oncology Group(ECOG)
             Performance Status 0 or 1

          4. Early-stage TNBC or HER2 positive breast cancer according to the American Joint
             Committee on Cancer (AJCC) Staging Manual Clinical Stage IIA or IIB, Stage IIIA
             operable breast cancer

          5. Previously untreated

          6. Adequate hematologic function (absolute neutrophil count ≥ 1,500 cells/µL; hemoglobin
             > 9 g/dL, platelets > 100,000/µL.)

          7. Adequate hepatic function: total bilirubin ≤ upper limit of normal (ULN), serum
             albumin ≥≥ 3.0 g/dL, alanine aminotransferase and aspartate aminotransferase ≤ 1.5 x
             ULN.

        Exclusion Criteria:

          1. ICH:ER/PgR status positive

          2. HER2 positive breast cancer Patients with reduced ejection fraction <50% are not
             eligible

          3. Patients with second malignancies

          4. Patients with bilateral breast cancer

          5. allergic constitution
      